The Use of Leucocyte Platelet Rich Fibrin (L- PRF) Covered Perforated Guided Tissue Membrane for Treatment of Periodontal Intrabony Defects

A randomized (controlled) clinical trial which included forty sites with intrabony interproximal defects (2- or 3-wall) premolar/molar teeth assessed for clinical parameters. The four treatment modalities were randomly allocated by a predetermined computer generated randomization list (www.randomizer.org) into four equal groups; Group I (control group) open flap debridement (OFD): included intrabony defects treated by open flap debridement (OFD).Group II perforated membrane (PM): included intrabony defects treated by perforated membranes.Group III Leucocyte-platelet rich fibrin (L-PRF): included intrabony defects treated by leukocytes platelet rich fibrin (L-PRF). Group IV Leucocyte-platelet rich fibrin + perforated membrane (L-PRF + PM): included intrabony defects treated by Leucocyte platelet rich fibrin & perforated membranes.

Inclusion criteria

• Both genders aged from 18- 60 years.
• Patients free from any systemic diseases that may contra-indicate periodontal surgery (Ahmed Y. Gamal et al., 2014).
• Two- or three-wall intrabony defects in premolar/molar teeth without furcation involvement, that are measured from the alveolar crest to the defect bottom in diagnostic periapical radiographs of ≥ 3 mm (Reynolds et al., 2015).
• Probing depth ≥ 5 mm and clinical attachment loss ≥ 4 mm at the site of intrabony defects 4 week after the phase one therapy (Ahmed Y. Gamal et al., 2014).
• Free from any periapical pathosis.
• Patients willing and able to return for multiple follow up visits and perform oral hygiene instructions.
• Absence of occlusal interference, mobility and open interproximal contact.
• Good fulfillment to plaque control instructions following initial therapy.

Exclusion criteria

• Smokers.
• Pregnant and breast feeding females.
• Periodontal surgical treatment in the previous 12 months at the involved sites. (A. Y. Gamal et al., 2016)
• Persistence of gingival inflammation after phase I therapy.
• Vulnerable groups as handicapped, mentally disabled, prisoners and orphans.